Synopsis of recent research by authors named "Alaka Mullick"
- Alaka Mullick's research primarily focuses on the production of biologics, particularly adeno-associated virus (AAV) vectors and monoclonal antibodies (mAbs), utilizing mammalian cell cultures like CHO cells, with an emphasis on improving yield and production efficiency.
- Recent findings highlight that only a small fraction of cells produce effective AAV capsids during transfection, and reducing recombinant protein expression during CHO cell pool selection can enhance the frequency of high-producing clones.
- Mullick's studies also involve the design of therapeutic antibodies, including the ADAPT platform to fine-tune binding affinities, alongside understanding genetic susceptibility to infections, with implications for antifungal therapy targeting gene expression modifications.
